Grape King Bio Ltd.
TTWSE:170785.20
TWD
-0.40
(-0.47%)
ISIN
TW0001707008
Return %
Stock
S&P 500
1Y
-31.57
14.20
3Y
-43.20
81.12
5Y
-47.57
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Sheng Lin Tseng
- Full Time Employees
- 501
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Jinling Road Taoyuan TYC Taiwan 324
- IPO Date
- Dec 20, 1982
- Website
- grapeking.com.tw
- Similar Companies
- Business
- Grape King Bio Ltd operates as a biotechnology company specializing in the development, manufacture, and sale of health food products, pharmaceutical preparations, and functional beverages. Its main product portfolio includes Chinese herbal medicines, probiotic supplements, energy drinks, and health food supplements targeting gastrointestinal health, immunity regulation, female beauty, and general health care. The company provides OEM/ODM services with advanced manufacturing capabilities such as capsules, sachets, glass bottles, aseptic filling packaging, and retort pouch production lines. Its products are marketed primarily in Taiwan, China, Southeast Asia, and other international markets. Founded in 1969 and headquartered in Taiwan, Grape King Bio leverages a robust R&D team that focuses on mushroom mycelium-based ingredients (including Ganoderma lucidum, Antrodia cinnamomea, Hericium erinaceus) and functional probiotics, supported by numerous patents, clinical studies, and international quality certifications. In recent years, Grape King Bio has strategically expanded its operations by entering partnerships and joint ventures, including a significant collaboration with Uni-President Enterprises Corporation, which acquired an 8% stake in Grape King in 2020. This alliance has enabled greater penetration into the fast-moving consumer goods (FMCG) market and retail channels. Additionally, Grape King Bio has advanced its global pharmaceutical business by beginning probiotic product shipments to a leading global pharmaceutical company and expanding sales channels into Southeast Asia, with Malaysia as a key growth market. The company has further demonstrated commitment to sustainable development by joining RE100, adopting net zero emission targets validated by the Science-based Targets Initiative, and implementing international environmental and anti-bribery management standards. It operates multiple production and research facilities in Taiwan including its headquarters, manufacturing sites, and biotech research institutes. Grape King Bio’s recent product innovations include new health supplements and functional beverages co-developed with partners like Uni-President, aiming at enhancing consumer health benefits and expanding market reach. The company maintains a leadership position in biotechnology-driven health food production with capabilities in fermentation technology and high-standard quality control to meet international food safety and pharmaceutical-grade standards. This comprehensive approach positions Grape King Bio Ltd as a leading biotechnology company focused on health food and pharmaceutical products, leveraging scientific innovation, strategic alliances, and sustainability to drive growth in regional and global markets.